Compounds, particularly compounds having spleen tyrosine kinase (Syk) inhibition activity, having the following structure: ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is structure (a), (b), (c) or (d): ##STR00002## and R.sup.a, R.sup.b, R.sup.c, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as defined herein. Methods associated with preparation and use of the same, as well as pharmaceutical compositions containing the same, are also disclosed, as well as uses of the same to treat a condition or disorder mediated by a Syk and/or JAK kinase.